[Progress of molecularly targeted therapy for breast cancer].
Yoshinori
Y
Ito
D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000235:genetics; D000069448:Denosumab; D015195:Drug Design; D004359:Drug Therapy, Combination; D000068338:Everolimus; D006801:Humans; D000077341:Lapatinib; D000077289:Letrozole; D008453:Maytansine / Q000031:analogs & derivatives; D058990:Molecular Targeted Therapy; D009570:Nitriles / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D020123:Sirolimus / Q000031:analogs & derivatives; D013629:Tamoxifen / Q000627:therapeutic use; D000068878:Trastuzumab; D014230:Triazoles / Q000627:therapeutic use
D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized; D000069448:Denosumab; D000068338:Everolimus; D000077341:Lapatinib; D000077289:Letrozole; D008453:Maytansine; D009570:Nitriles; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D020123:Sirolimus; D013629:Tamoxifen; D000068878:Trastuzumab; D014230:Triazoles; C508053:ERBB2 protein, human